Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer

Area of Science:

• Oncology
• Immunotherapy
• Gastroenterology

Background:

• Targeted therapy and immunotherapy have advanced cancer treatment.
• Trastuzumab therapy in Her2-positive gastric cancer shows limited survival benefits due to progression and toxicity.
• Ideal monoclonal antibodies (IMAB) targeting tumor-specific proteins are under development to minimize side effects.

Purpose of the Study:

• To review the development of claudiximab, a novel antibody targeting claudin 18.2.
• To highlight claudiximab as a potential first-in-class IMAB for gastric cancer treatment.

Main Methods:

• Review of latest developments in claudiximab research.
• Focus on claudin 18.2 as a tumor-specific target in gastric cancer.

Main Results:

• Claudin 18.2 is identified as a protein specific to several cancers, including gastric cancer and its metastases.
• Claudiximab, an anti-claudin 18.2 antibody, has been developed.

Conclusions:

• Claudiximab represents a promising new therapeutic strategy for gastric cancer.
• This first-in-class IMAB has the potential to improve patient outcomes by targeting tumor-specific antigens.